Mylan Settles Out Of Diabetes Drug Patent Fight At PTAB
Just as co-challenger Pfizer wrapped up arguments Friday before the Parent Trial and Appeal Board, Mylan revealed it had worked out its differences with Novo Nordisk over the latter drugmaker's patent...To view the full article, register now.
Already a subscriber? Click here to view full article